| Identification | Back Directory | [Name]
1(2H)-Quinazolineacetamide, 3-[4-[(1,3-benzodioxol-5-ylmethyl)amino]-4-oxobutyl]-N-(3-chlorophenyl)-3,4-dihydro-2,4-dioxo- | [CAS]
899937-47-4 | [Synonyms]
1(2H)-Quinazolineacetamide, 3-[4-[(1,3-benzodioxol-5-ylmethyl)amino]-4-oxobutyl]-N-(3-chlorophenyl)-3,4-dihydro-2,4-dioxo-
N-(benzo[d][1,3]dioxol-5-ylmethyl)-4-(1-(2-((3-chlorophenyl)amino)-2-oxoethyl)-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl)butanamide
N-(Benzo[d][1,3]dioxol-5-ylmethyl)-4-[1-[2-[(3-chlorophenyl)amino]-2-oxoethyl]-2,4-dioxo-1,2-dihydroquinazolin-3(4H)-yl]butanamide | [Molecular Formula]
C28H25ClN4O6 | [MOL File]
899937-47-4.mol | [Molecular Weight]
548.97 |
| Hazard Information | Back Directory | [Uses]
WRX606 is an inhibitor for mTOR complex 1 (mTORC1). WRX606 inhibits the phosphorylation of mTORC1 substrate S6 kinase 1 S6K1 (IC50=10 nM), and the phosphorylation of the eukaryotic translation initiation factor 4E binding protein (p-4E-BP1) (IC50=0.27 μM) in MCF-7. WRX606 exhibits cytotoxicity to HepG2 with IC50 of 17 nM. WRX606 exhibits antitumor efficacy in mouse models[1]. | [References]
[1] Shams R, et al., In Silico and In Cell Hybrid Selection of Nonrapalog Ligands to Allosterically Inhibit the Kinase Activity of mTORC1. J Med Chem. 2022 Jan 27;65(2):1329-1341. DOI:10.1021/acs.jmedchem.1c00536 |
|
|